
|Videos|June 11, 2021
Secukinumab Approved for Plaque Psoriasis in Children, Adolescents
Author(s)Linda Stocum, Associate Editor
John Browning, MD, FAAD, FAAP, MBA, discusses the impact of the recent FDA approval of secukinumab (Cosentyx, Novartis) for the treatment of moderate to severe plaque psoriasis in children and adolescents.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: The Summer Skin Care "Shutdown"
2
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
3
ED Treatment Gaps Persist for Pediatric Atopic Dermatitis
4
Soficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe AD
5











